Convergent evolution and multi-wave clonal invasion in H3 K27-altered diffuse midline gliomas treated with a PDGFR inhibitor

被引:0
|
作者
Sasi Arunachalam
Karol Szlachta
Samuel W. Brady
Xiaotu Ma
Bensheng Ju
Bridget Shaner
Heather L. Mulder
John Easton
Benjamin J. Raphael
Matthew Myers
Christopher Tinkle
Sariah J. Allen
Brent A. Orr
Cynthia J. Wetmore
Suzanne J. Baker
Jinghui Zhang
机构
[1] St. Jude Children’s Research Hospital,Department of Computational Biology
[2] Princeton University,Department of Computer Science
[3] St. Jude Children’s Research Hospital,Departments of Radiation Oncology
[4] Thermofisher,Departments of Pathology
[5] St. Jude Children’s Research Hospital,Clinical Development
[6] Neoleukin,Department of Developmental Neurobiology
[7] St. Jude Children’s Research Hospital,undefined
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The majority of diffuse midline gliomas, H3 K27-altered (DMG-H3 K27-a), are infiltrating pediatric brain tumors that arise in the pons with no effective treatment. To understand how clonal evolution contributes to the tumor’s invasive spread, we performed exome sequencing and SNP array profiling on 49 multi-region autopsy samples from 11 patients with pontine DMG-H3 K27-a enrolled in a phase I clinical trial of PDGFR inhibitor crenolanib. For each patient, a phylogenetic tree was constructed by testing multiple possible clonal evolution models to select the one consistent with somatic mutations and copy number variations across all tumor regions. The tree was then used to deconvolute subclonal composition and prevalence at each tumor region to study convergent evolution and invasion patterns. Somatic variants in the PI3K pathway, a late event, are enriched in our cohort, affecting 70% of patients. Convergent evolution of PI3K at distinct phylogenetic branches was detected in 40% of the patients. 24 (~ 50%) of tumor regions were occupied by subclones of mixed lineages with varying molecular ages, indicating multiple waves of invasion across the pons and extrapontine. Subclones harboring a PDGFRA amplicon, including one that amplified a PDGRFAY849C mutant allele, were detected in four patients; their presence in extrapontine tumor and normal brain samples imply their involvement in extrapontine invasion. Our study expands the current knowledge on tumor invasion patterns in DMG-H3 K27-a, which may inform the design of future clinical trials.
引用
收藏
相关论文
共 50 条
  • [21] High-plex spatial multiomics of pediatric and adult diffuse midline glioma, H3 K27-altered
    Damodharan, Sudarshawn
    Rosenbloom, Alyssa
    Dey, Mahua
    CANCER RESEARCH, 2023, 83 (07)
  • [22] Identification of prognostic imaging biomarkers in H3 K27-altered diffuse midline gliomas in adults: impact of tumor oxygenation imaging biomarkers on survival
    Sim, Yongsik
    Choi, Kaeum
    Han, Kyunghwa
    Choi, Seo Hee
    Lee, Narae
    Park, Yae Won
    Shin, Na-Young
    Ahn, Sung Soo
    Chang, Jong Hee
    Kim, Se Hoon
    Lee, Seung-Koo
    NEURORADIOLOGY, 2024, 66 (09) : 1581 - 1591
  • [23] H3 K27-altered diffuse midline glioma of the thalamus with formation of glio-fibrillary globular structures
    Shintaku, Masayuki
    Hashiba, Tetsuo
    Nonaka, Masahiro
    Asai, Akio
    Tsuta, Koji
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2024, 17 (07): : 227 - 233
  • [24] A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered
    Jackson, Evangeline R.
    Persson, Mika L.
    Fish, Cameron J.
    Findlay, Izac J.
    Mueller, Sabine
    Nazarian, Javad
    Hulleman, Esther
    van der Lugt, Jasper
    Duchatel, Ryan J.
    Dun, Matthew D.
    NEURO-ONCOLOGY, 2024, 26 : S136 - S154
  • [25] TRANSCRIPTIONAL, EPIGENETIC, AND IMMUNOLOGICAL FEATURES OF PAEDIATRIC-TYPE H3 K27-ALTERED DIFFUSE MIDLINE GLIOMAS ORIGINATING FROM DIFFERENT BRAIN LOCATIONS
    Grabovska, Yura
    Mackay, Alan
    Pereira, Rita
    Sejdiu, Drenusha
    Burford, Anna
    Temelso, Sara
    Clarke, Matt
    Jones, Chris
    NEURO-ONCOLOGY, 2023, 25
  • [26] Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies
    Rechberger, Julian S.
    Bouchal, Samantha M.
    Power, Erica A.
    Nonnenbroich, Leo F.
    Nesvick, Cody L.
    Daniels, David J.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2023, 27 (11) : 1071 - 1086
  • [27] Fulminant hemorrhagic course of a thalamic H3 K27-altered diffuse midline glioma in an adult patient: illustrative case
    Poletti, Nicolas
    Marques, Luca Lee
    Deigendesch, Nikolaus
    Soleman, Jehuda
    Mariani, Luigi
    Guzman, Raphael
    Rychen, Jonathan
    JOURNAL OF NEUROSURGERY-CASE LESSONS, 2024, 7 (04):
  • [28] Diffuse midline gliomas H3 K27M-mutant: An update
    Sarkar, Chitra
    Kaur, Kavneet
    Kumar, Anupam
    Pathak, Pankaj
    Suri, Vaishali
    Sharma, Mehar Chand
    Garg, Ajay
    Suri, Ashish
    BRAIN PATHOLOGY, 2019, 29 : 138 - 138
  • [29] DIFFUSE MIDLINE GLIOMAS, H3K27-ALTERED AS AN INTERDISCIPLINARY CHALLENGE
    Kammler, Gertrud
    Fritzsche, Friederike
    Kordes, Uwe
    Schueller, Ulrich
    Westphal, Manfred
    NEURO-ONCOLOGY, 2022, 24 : 28 - 28
  • [30] Feasibility of probe washing after stereotactic needle biopsy as a novel technique for developing cell lines and xenografts of H3 K27-altered diffuse midline gliomas
    Rechberger, Julian S.
    Zhang, Liang
    Ge, Jizhi
    Nesvick, Cody L.
    Miller, Kai J.
    Daniels, David J.
    JOURNAL OF NEUROSURGERY-PEDIATRICS, 2023, 32 (04) : 413 - 420